Milan, Italy, October 27, 2022 (GLOBE NEWSWIRE) - AGC Biologics , one of the leading global organizations for the development and manufacturing of biopharmaceutical contracts (CDMO), announced today that it has received the Excellence in Innovation and Leadership Award from Le Fonti, at an awards ceremony on 6 October. The company was awarded for the work of its headquarters in Milano , which helps produce cell and gene therapy treatments for biotech companies for clinical and commercial applications.
The ceremony took place at the prestigious Palazzo Mezzanotte, headquarters of the Italian Stock Exchange, and saw AGC Biologics award the Excellence in Innovation and Leadership in the Healthcare sector for its leadership position in the Cell & Gene Therapy sector, its profound technical excellence and the critical work of the research and development department focused on introducing innovative platforms and solutions to the market.
The Le Fonti Awards recognize outstanding organizations and their leaders who demonstrate business excellence in business innovation, leadership, technology achievement and employee engagement. Luca Alberici, General Manager of AGC Biologics Milan, received the award together with key members of the management team of the Milan site.
“We are honored to accept this award and it is a great privilege to work with such a strong team of scientists and experts at the AGC Biologics headquarters in Milan,” said Alberici. "Our teams are committed to bringing new innovations to cell and gene therapies and we are proud to help create life-saving treatments with our partners that can impact patients around the world."
AGC Biologics Milano offers end-to-end services for cell therapy and development and production of viral vectors. The facility was also the first GMP approved facility in Europe for the production of ex vivo gene therapies and has a unique commercial manufacturing experience in the industry. Since joining AGC Biologics' global network in 2020, AGC Biologics has invested in innovations to expand their capabilities and production capabilities . AGC Biologics Milano scientists have several decades of experience guiding advanced therapy products through key product stages, including the development of three commercial products.
To learn more about the AGC Biologics Milano facility and its cell therapy and viral vector services, visit www.agcbio.com/facilities/milan .
AGC Biologics is a leading global biopharmaceutical contract development and manufacturing (CDMO) organization with a strong commitment to providing the highest standards of service as we work hand in hand with our customers and partners, every step of the way. We provide world-class development and manufacturing of mammalian and microbial therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors and genetically modified cells.
Our global network spans the United States, Europe and Asia, with cGMP compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and currently employ more than 2.000 employees worldwide. Our commitment to continuous innovation fosters technical creativity to solve our customers' most complex challenges, including specializing in accelerated projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com .
Google DeepMind is introducing an improved version of its artificial intelligence model. The new improved model provides not only…
Laravel, famous for its elegant syntax and powerful features, also provides a solid foundation for modular architecture. There…
Cisco and Splunk are helping customers accelerate their journey to the Security Operations Center (SOC) of the future with…
Ransomware has dominated the news for the last two years. Most people are well aware that attacks…
An ophthalmoplasty operation using the Apple Vision Pro commercial viewer was performed at the Catania Polyclinic…
Developing fine motor skills through coloring prepares children for more complex skills like writing. To color…
The naval sector is a true global economic power, which has navigated towards a 150 billion market...
Last Monday, the Financial Times announced a deal with OpenAI. FT licenses its world-class journalism…
